R Vettor, R Serra, R Fabris, C Pagano, G … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Eight placebo-controlled, double-blind, randomized trials of
sibutramine were included. After sibutramine treatment, the decrease in body
weight and waist circumference was significantly greater than in the ... Cited by 71 - Related articles - All 5 versions
SL Norris, X Zhang, A Avenell, E Gregg, CH … - Archives of internal medicine, 2004 - Am Med Assoc Results Sufficient data for the meta-analysis were available for fluoxetine,
orlistat, and sibutramine. Fourteen randomized, placebo-controlled trials were
included in the review, with a total of 2231 patients. Pharmacotherapy ... Cited by 90 - Related articles - BL Direct - All 5 versions
SL Norris, X Zhang, A Avenell, E Gregg, CH … - Cochrane Database Syst Rev, 2005 - medscape.com Obesity is closely related to type 2 diabetes and long – term weight reduction
is an important part of the care delivered to obese persons with diabetes. ...
To assess the efficacy of pharmacotherapy for weight loss in adults with ... Cited by 43 - Related articles - All 6 versions
SH Kim, YM Lee, SH Jee, CM Nam - Obesity, 2003 - nature.com Results: The effect size of sibutramine on weight change was -1.00 (-1.17 to
-0.84), whereas the effect sizes on SBP and DBP changes were 0.16 (0.08 to 0.24)
and 0.26 (0.18 to 0.33), respectively. By subgroup analysis, the effect ... Cited by 55 - Related articles - BL Direct - All 3 versions
- Free from Publisher DE Kelley, GA Bray, FX Pi-Sunyer, S Klein, J … - Diabetes Care, 2002 - Am Diabetes Assoc OBJECTIVE—Weight loss improves glycemic control, lipid profiles, and blood
pressure in patients with type 2 diabetes. However, successful long-term weight
loss is difficult for these patients, particularly those treated with ... Cited by 172 - Related articles - BL Direct - All 7 versions
- Free from Publisher SJ McNulty, E Ur, G Williams - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Sibutramine induced significant weight loss (P < 0.001) with both 15
mg/day (5.5 ± 0.6 kg at 12 months) and 20 mg/day (8.0 ± 0.9 kg), whereas
placebo did not (0.2 ± 0.5 kg). Weight loss ≥10% was achieved by 14 and ... Cited by 97 - Related articles - BL Direct - All 6 versions
- Free from Publisher JM Miles, L Leiter, P Hollander, T Wadden, JW … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—After 1 year of treatment, mean (±SE) weight loss was greater in the
orlistat than in the placebo group (−4.6 ± 0.3% vs. −1.7 ± 0.3% of
baseline wt, P < 0.001). Orlistat treatment caused a greater improvement in ... Cited by 171 - Related articles - BL Direct - All 7 versions
- ►endojournals.org A Godoy-Matos, L Carraro, A Vieira, J … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Adolescent obesity is becoming a health problem in both developed and developing
countries. Antiobesity drug therapy is not currently indicated for the treatment
of adolescent obesity and remains investigational at this time. The aim of ... Cited by 97 - Related articles - All 8 versions
TA Wadden, RI Berkowitz, LG Womble, DB … - Obesity, 2000 - nature.com Research Methods and Procedures: Patients were 34 women with a mean age of 44.1
10.4 years, weight of 89.4 13.8 kg, and body mass index (BMI) of 33.9 4.9 kg/m 2
who had lost an average of 11.6 9.2% of initial weight during the prior 1 ... Cited by 112 - Related articles - BL Direct - All 2 versions
A Kaya, N Aydın, P Topsever, M Filiz, A Öztürk, … - Biomedicine & Pharmacotherapy, 2004 - Elsevier Results. – The four interventional groups displayed decreases in BMI as
follows: (1) –4.41 ± 1.26 kg/m 2 ; (2) –3.64 ± 0.97 kg/m 2 ; (3) –5.12
± 1.44 kg/m 2 and (4) –2.52 ± 1.36 kg/m 2 ; with the diet group showing ... Cited by 40 - Related articles - All 6 versions
